Drug Eluting Stents (DES) are proven to reduce the risk of restenosis and improve outcomes for patients with more complex coronary disease. However, in certain patients where there is a requirement to avoid prolonged Dual Anti-Platelet Therapy (DAPT), Bare Metal Stents (BMS) may be preferred. BioFreedom™, as a Drug-Coated Stent (DCS), combines the advantages of both DES and BMS. It delivers an effective anti-restenotic therapy with Biolimus A9™, and may shorten the required DAPT1 regime.
- Characteristics: : drug eluting
- Cardiovascular system : : coronary